Hereditary Leiomyomatosis and Renal Cell Carcinoma
3 clinical trials · Condition
◉ Watch Hereditary Leiomyomatosis and Renal Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer (NCT07716735) | Jonsson Comprehensive Cancer Center | 2026-12-01 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (NCT04981509) | National Cancer Institute (NCI) | 2022-06-10 |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer (NCT04603365) | Jonsson Comprehensive Cancer Center | 2021-10-18 |
Track Hereditary Leiomyomatosis and Renal Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.